Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Completed 662 enrolled Intuor Technologies, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

Prospective, randomized, double-masked, placebo-controlled clinical study to define the effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema.

Timeline

Start: 2013-10
Primary completion: 2017-01
Completion: 2017-01

Outcome

Met primary endpoint

paper Topical nepafenac 0.3% significantly reduces the incidence of PCME compared to placebo when used after routine cataract surgery (p = .0001). PMID 28219426 ↗

Publications

McCafferty S, Harris A, Kew C, Kassm T, Lane L, Levine J, Raven M. Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. BMC Ophthalmol. 2017 Feb 20;17(1):16. doi: 10.1186/s12886-017-0405-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nepafenac	Other / unclassified	0.3 %	Topical